CompletedPhase 1NCT01658839
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
Studying Congenital glaucoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alcon Research
- Principal Investigator
- Subha VenkataramanAlcon Research
- Intervention
- Travoprost ophthalmic solution, 0.004% (new formulation)(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2013 – 2013
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01658839 on ClinicalTrials.govOther trials for Congenital glaucoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT06969586The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal DystrophyUniversity Hospital Dubrava
- ACTIVE NOT RECRUITINGNANCT06837610Inverted T Trabeculectomy Primary Congenital GlaucomaBenha University
- RECRUITINGNANCT04129021High Resolution, High-speed Multimodal Ophthalmic ImagingCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- RECRUITINGNCT02014389Evaluation of Objective Perimetry Using Chromatic Multifocal PupillometerSheba Medical Center